依那西普治疗非全身型幼年特发性关节炎的近期疗效及安全性观察

摘要

目的 观察依那西普治疗非全身型幼年特发性关节炎的疗效和安全性.方法 对30例非全身型幼年特发性关节炎患儿皮下注射依那西普0.4 mg/(kg·次),每周2次,在治疗后1周、1个月及3个月采用ACRPedi 30/50/70评分进行疗效评估.结果 治疗后1周、1月及3月时ACR Pedi 30达标率分别为16.70%、90.00%、96.67%,ACR Pedi 50达标率分别为3.30%、30.00%、66.70%,ACR Pedi 70达标率分别为0、0、16.70%(5),且无重大不良事件发生.结论 依那西普治疗非全身型幼年特发性关节炎具有较好的近期疗效,在病程早期使用效果更显著,不良反应小且发生率低.%Objective To observe the short-term clinical efficacy and safety of etanercept in treatment of nonsystemic juvenile idiopathic arthritis ( JIA). Methods Thirty patients with non-systemic JIA were subcutaneously injected with etanercept 0.4 mg/kg twice a week. Clinical efficacy was evaluated based on ACR pedi 30/50/70 score 1 week, 1 month, 3 months atter treatment Results One week, 1 month and 3 months after treatment the ACR Pedi 30 compliance rates were 16.70％ ( 5 ), 90.00％ ( 27 ) and 96.67％ ( 29 ), ACR Pedi 50 compliance rates were 3.30％ ( 1 ), 30.00％ ( 9 ) and 66.70％ ( 20 ), and ACR pedi 70 compliance rates were 0, 0 and 16.70％ ( 5 ). Meanwhile no significant adverse event happened. Conclusions Etanercept has a favorable short-term effect in treatment of nonsystemic JIA. The clinical efficacy is more significant in early course of disease. The adverse events are few and minor.